Atrion Reports First Quarter Results ALLEN,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atrion Reports First Quarter Results

ALLEN, TX--(Marketwired - May 6, 2015) - Atrion Corporation ( NASDAQ : ATRI ) today announced diluted earnings per share for the first quarter of 2015 were $4.01 as compared to $3.61 in the first quarter of 2014. Revenues for the quarter ended March 31, 2015 were $38.3 million compared with $36.4 million in the same period in 2014. Net income in the current-year quarter totaled $7.6 million compared to $7.2 million in last year's first quarter.

Commenting on the Company's results for the first quarter of 2015 compared to the same period last year, David A. Battat, President & CEO, said, "We are pleased with the increased revenues in our cardiovascular and fluid delivery products that resulted in an overall sales increase of 5% despite flat results in the ophthalmic area. As we continue to expand our new product pipeline, investments in R&D in the current-year quarter increased $385,000 over those for the same period of 2014. Nevertheless, operating income for the quarter was up 7%. If R&D expenses had been the same as in the prior-year period, our operating income would have been 11% higher." Mr. Battat continued, "In prior years, tax rate comparisons have fluctuated widely due to the inconsistent timing of R&D tax credit extensions. Tax rates in the first quarters of 2014 and 2015 were essentially similar, as Congress did not extend these credits in either period. Benefiting from both stable tax rates and stock repurchases over the past twelve months, diluted earnings per share were up 11% over those of the 2014 period." Mr. Battat added, "During the quarter we invested $17.0 million to repurchase 50,157 shares of our common stock, while continuing to hold cash and short and long term investments of $32.6 million as of March 31, 2015."

Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com .

   
ATRION CORPORATION  
CONSOLIDATED STATEMENTS OF INCOME  
(In thousands, except per share data)  
(Unaudited)  
   
    Three Months Ended March 31,  
    2015     2014  
Revenues   $ 38,324     $ 36,419  
Cost of goods sold     19,800       19,031  
  Gross profit     18,524       17,388  
Operating expenses     7,038       6,688  
  Operating income     11,486       10,700  
                 
Interest income     177       300  
Other income (expense), net     --       1  
  Income before income taxes     11,663       11,001  
Income tax provision     (4,061 )     (3,800 )
  Net income     7,602       7,201  
                 
                 
Income per basic share   $ 4.05     $ 3.63  
                 
Weighted average basic shares outstanding     1,875       1,982  
                 
                 
Income per diluted share   $ 4.01     $ 3.61  
                 
Weighted average diluted shares outstanding     1,895       1,997  
                 
 
ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
 
    Mar. 31,     Dec. 31,
ASSETS   2015     2014
    (Unaudited)      
Current assets:              
  Cash and cash equivalents   $ 15,871     $ 20,775
  Short-term investments     3,189       3,084
    Total cash and short-term investments     19,060       23,859
  Accounts receivable     21,407       16,962
  Inventories     26,747       28,022
  Prepaid expenses and other     1,400       4,720
  Deferred income taxes     573       573
    Total current assets     69,187       74,136
               
Long-term investments     13,529       21,760
               
Property, plant and equipment, net     63,074       62,516
Other assets     13,200       13,102
               
    $ 158,990     $ 171,514
               
               
LIABILITIES AND STOCKHOLDERS' EQUITY              
               
  Current liabilities     7,110       9,936
  Line of credit     --       --
  Other non-current liabilities     12,577       12,008
  Stockholders' equity     139,303       149,570
               
    $ 158,990     $ 171,514
               
 
NON-GAAP FINANCIAL MEASURE RECONCILIATION
(In thousands)
 

Included in our news release is a non-GAAP financial measure that is calculated by excluding certain expenses that are included in financial measures determined in accordance with GAAP. We have provided this non-GAAP measure as an additional tool for investors to better understand our operating results and to facilitate a comparison of the periods shown. This measure should be considered in addition to, rather than as a substitute for, GAAP measures of the Company's performance. The table below provides a reconciliation of this non-GAAP financial measure with the most directly comparable GAAP financial measure.

         
    Three Months Ended March 31,   %
    2015   2014   Increase
GAAP operating income   $11,486   $10,700   7%
Adjustment for increase in R&D expenses   385        
Adjusted non-GAAP operating income   $11,871   $10,700   11%
             

Contact: Jeffery Strickland Vice President and Chief Financial Officer (972) 390-9800

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 55

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Regulatory T-Cells Market Growth Driven by New Therapies

Updated Category News Views 217

Insights into the Regulatory T-Cells Market Growth The landscape of the Treg therapy market is rapidly evolving as companies globally actively develop innovative regulatory T-cell therapies to treat various critical conditions. These include systemic lupus erythematosus (SLE), lupus nephritis, atopic dermatitis, rheumatoid arthritis, psoriasis, progressive multiple...

Continue Reading
Natural Grocers Unveils Autumnfest Super Savings Event

Updated Category News Views 67

Natural Grocers Introduces Autumnfest Savings Event As the autumn leaves begin to fall, Natural Grocers invites shoppers to revel in the festivities of the season with their exciting Autumnfest Savings Event. This annual celebration promises customers an incredible opportunity to enjoy significant discounts, free samples, and delightful seasonal recipes. With savings of...

Continue Reading
Anthem Blue Cross Commits $10 Million for Wildfire Relief

Updated Category News Views 270

Anthem Blue Cross Generously Assists Communities Affected by Wildfires For over eight decades, Anthem Blue Cross has maintained a strong presence in California, prioritizing the health and well-being of its residents. Our focus has always been on putting people first, as we acknowledge the struggles that come with disasters that can significantly impact the lives of our...

Continue Reading
Corporate Legal Departments Face Major Workforce Challenges

Updated Category News Views 179

Corporate Legal Departments Face Major Workforce Challenges In the evolving landscape of corporate legal departments, a significant wave of attrition is looming as in-house attorneys express a desire to seek better opportunities. The increase in workloads, coupled with concerns about artificial intelligence and limited career advancement prospects, has prompted many legal...

Continue Reading
Currax Achieves FDA Approval for Enhanced CONTRAVE Supply Chain

Updated Category News Views 411

Currax Expands Manufacturing Capabilities for CONTRAVE Currax Pharmaceuticals LLC, a focused specialty pharmaceutical company, recently announced a significant milestone in its operations. The U.S. Food and Drug Administration (FDA) has granted approval for a second manufacturing facility dedicated to the production of CONTRAVE (naltrexone HCl/bupropion HCl), a leading...

Continue Reading